Previous Article | Next Article 
J Virol, May 1998, p. 4524-4527, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Single Amino Acid Insertion in Loop 4 Confers
Amphotropic Murine Leukemia Virus Receptor Function upon Murine
Pit1
Mikkel D.
Lundorf,1
Finn S.
Pedersen,1,2
Bryan
O'Hara,3 and
Lene
Pedersen1,*
Department of Molecular and Structural
Biology1 and
Department of Medical
Microbiology and Immunology,2 University of
Aarhus, DK-8000 Aarhus C, Denmark, and
Department of Molecular
Biology, Wyeth-Ayerst Research, Pearl River, New York
109653
Received 16 October 1997/Accepted 28 January 1998
 |
ABSTRACT |
Pit1 is the human receptor for gibbon ape leukemia virus (GALV) and
feline leukemia virus subgroup B (FeLV-B), while the related human
protein Pit2 is a receptor for amphotropic murine leukemia virus
(A-MuLV). The A-MuLV-related isolate 10A1 can utilize both Pit1 and
Pit2 as receptors. A stretch of amino acids named region A was
identified in Pit1 (residues 550 to 558 in loop 4) as critical for GALV
and FeLV-B receptor function. We have here investigated the role of
region A in A-MuLV and 10A1 entry. Insertion of a single amino acid in
region A of mouse Pit1 resulted in a functional A-MuLV receptor,
showing that region A plays a role in A-MuLV infection. Moreover, the
downregulation of 10A1 receptor function by changes in region A of
human Pit1 indicates that this region is also involved in 10A1 entry.
Therefore, region A seems to play a role in infection by all viruses
utilizing Pit1 and/or Pit2 as receptors.
 |
TEXT |
Retroviruses are dependent on
specific cell surface receptors for infection. Recently, two related
proteins were identified as receptors for different C-type viruses.
Pit1 (formerly GLVR1) was cloned as the human receptor for gibbon ape
leukemia virus (GALV) (16) and is also a receptor for feline
leukemia virus subgroup B (FeLV-B) (24). In addition, a
number of Pit1 homologs from other species have been cloned (9,
10, 28, 29); however, not all of these support GALV and FeLV-B
infection, e.g., that from mice (Mus musculus musculus)
(MusPit1, formerly Glvr1) (9). A related protein, Pit2, was
cloned as receptor for the amphotropic murine leukemia virus (A-MuLV)
from rats (RatPit2, formerly Ram-1), humans (Pit2, formerly GLVR2), and
hamsters (HaPit2, formerly EAR) (15, 26, 29). Miller and
Miller demonstrated that Pit1, MusPit1, Pit2, and RatPit2 proteins are
receptors for the A-MuLV-related isolate 10A1 (14).
Furthermore, by interference studies, 10A1 was shown also to utilize
Pit1 and Pit2 from hamsters for entry (29).
The cellular function of both Pit1 and Pit2 is sodium-dependent
phosphate transport (11, 17, 30), and the human forms of
these proteins have about 62% amino acid identity (26).
Both proteins are predicted to have 10 transmembrane domains, five extracellular loops, and a large intracellular hydrophilic domain between the sixth and seventh transmembrane domains (9, 26). This topological model is supported by recent results obtained on Pit2
topology by Chien and colleagues (5).
MusPit1 and human Pit1 differ in their amino acid sequences at only 64 positions, and in the putative extracellular loops, divergent residues
are found only in loops 2 and 4 (9). As mentioned above,
unlike Pit1, MusPit1 does not allow infection by GALV or FeLV-B and
chimeras between human and mouse Pit1 revealed a stretch of nine
residues named region A (Pit1 positions 550 to 558 in loop 4) as
critical for GALV and FeLV-B infection (10, 23). Moreover,
only chimeras between Pit1 and the less related Pit2 and RatPit2
proteins which harbored Pit1 region A were permissive for GALV and
FeLV-B entry, confirming the critical role of region A in receptor
function for these viruses (14, 21). FeLV-B was, however,
found also to be dependent on other Pit1 sequences in addition to
region A for infection (21). Recently, Chaudry and Eiden
have obtained results indicating that receptor regions in addition to
region A are also important for GALV entry (4).
Little is known about what specifies A-MuLV receptor function. Pit1 is
not an efficient A-MuLV receptor (6, 14, 21), and both the
N-terminal two-thirds (comprising loops 1, 2, and 3 and the
intracellular domain) and the C-terminal third (comprising loops 4 and
5) of the human and rat Pit2 proteins conferred A-MuLV receptor
function on Pit1-Pit2 hybrids (6, 14, 21). However, substitution of the human and rat Pit2 region A sequence alone for the
corresponding Pit1 sequence also conferred A-MuLV receptor function on
Pit1 (14, 21). At present, the receptor requirements of the
A-MuLV-related isolate 10A1 have not been studied.
To further examine the role of region A in A-MuLV receptor function, we
tested whether region A mutants generated from Pit1 or MusPit1 would
allow infection by A-MuLV. The same mutants were also assayed for 10A1
receptor function.
Expression plasmids encoding the MusPit1 and Pit1 region A mutants
shown in Table 1 were tested for their
ability to support A-MuLV and 10A1 infection in CHO K1 cells. The
construction of the plasmids has been described elsewhere
(10). Expression plasmids encoding wild-type
MusPit1 (pOJ19) (10), Pit1 (pOJ75), and Pit2 (pOJ74)
(21) were included as controls. The constructs were tested
for A-MuLV and 10A1 receptor function by a transient
transfection-infection assay essentially as described previously
(21). Briefly, CHO K1 cells (ATCC CCL-61) were seeded at
4 × 104 cells per 60-mm-diameter dish and transfected
the following day by the calcium phosphate-DNA precipitation method
(8). Each precipitate contained 10 µg of a CsCl-purified
expression plasmid and 5 µg of CsCl-purified pUC19 plasmid as carrier
in 1 ml. From each precipitate, aliquots of 200 µl, corresponding to
2 µg of expression plasmid, were added to two 60-mm-diameter dishes.
Forty-eight hours after transfection, dishes transfected with the same
construct were selected at random and challenged with A-MuLV or 10A1
pseudotypes in the presence of Polybrene (8 µg/ml). A-MuLV
pseudotypes of the
-galactosidase-encoding vector G1BgSvN
(12) were obtained from the producer cell line PA317GBN
(12, 13). 10A1 pseudotypes of the
-galactosidase-encoding
vector LNPOZ (1) were obtained by infecting an NIH 3T3 cell
clone harboring the LNPOZ construct with viruses derived from
plasmid pRR151, which encodes Moloney Gag-Pol and 10A1 Env proteins
(19). The titers of A-MuLV and 10A1 pseudotypes, determined
as previously described (21), were 105 and
104 CFU/ml on D17 cells (ATCC CCL-183), respectively.
Challenging of transfected cells with 10A1 pseudotypes was performed in
the presence of medium conditioned by CHO K1 cells to block the
endogenous 10A1 receptors (14). Forty-eight hours after
challenge, the cells were fixed in 0.05% glutaraldehyde and assayed
for
-galactosidase activity with X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) as
the substrate (25). The plates were examined for stained (blue) cells with a light microscope, and the number of blue cells per
dish was counted. The results obtained are shown in Table 1.
A role of region A in A-MuLV receptor function.
As previously
observed for Pit1 (6, 14, 21), Pit1 (pOJ75) and MusPit1
(pOJ19) did not efficiently support A-MuLV infection. Three expression
plasmids encoding Pit1-derived chimeras harboring either mouse Pit1
region A sequence (pOJ34), a scrambled Pit1 region A (pOJ36), or Pit1
region A with a deletion of aspartic acid at position 550 (pOJ71) also
did not promote A-MuLV infection. It is, however, not known whether the
proteins encoded by pOJ36 and pOJ71 are correctly processed, in that
they did not support infection by any of the tested viruses (Table 1)
(10). Interestingly, a MusPit1-derived protein with a
threonine inserted between lysine at position 553 and glutamine at
position 554 (pOJ64) afforded A-MuLV infection at a level about 60-fold
greater than that afforded by MusPit1 (pOJ19).
The observation that insertion of a single threonine residue in MusPit1
region A resulted in an efficient A-MuLV receptor
shows that region A
is involved in A-MuLV receptor function. This
result is in agreement
with the previous observation that Pit1
harboring Pit2/RatPit2 region A
sequence affords A-MuLV infection
(
14,
21).
Observations by us (
21) and others (
6,
14)
suggest, however, that region A alone does not specify A-MuLV receptor
function.
As mentioned above, both chimeras harboring the N-terminal
two-thirds
of Pit1 and the C-terminal third of Pit2 or RatPit2 and the
reciprocal
chimeras allowed efficient A-MuLV entry (
6,
14,
21). Thus,
identical region A sequences are present both in Pit1
with no
A-MuLV receptor function and in a chimeric A-MuLV receptor.
Moreover,
comparable chimeras in which the N- or C-terminal parts were
derived
from hamster Pit2 afforded only very low or no A-MuLV
infection,
respectively, although HaPit2 is as efficient an A-MuLV
receptor
as is RatPit2 (
6). In summary, these results
suggest that A-MuLV
receptor function is defined by a combination of
both N- and C-terminal
receptor domains. Therefore, although region A
is a C-terminal
determinant of A-MuLV receptor function (
14,
21; also this
study), the region A sequence requirements for
A-MuLV infection
might be predicted to differ depending on the protein
backbone.
Accordingly, no consensus region A sequence can be expected
to
be revealed by comparing region A sequences from all wild-type
and
chimeric proteins known to support A-MuLV entry. However,
comparison of
A regions permissive for A-MuLV infection when present
in identical or
homologous receptor backbones might be informative.
In Fig.
1 is shown a comparison of region
A sequences from wild-type Pit1 or Pit2 proteins tested for A-MuLV
receptor function
and of region A mutant proteins permissive for A-MuLV
infection
(
6,
9,
15,
16,
21,
26,
29; also this
study). Alignment
of region A sequences permissive for A-MuLV infection
in either
Pit1 or Pit2 backbones [receptors include Pit2, RatPit2,
HaPit2,
Pit2(K522E), pOJ64, pOJ80, and pOJ102] reveals that all nine
residues
can vary without affecting A-MuLV entry; only the differences
in positions 5 and 9 are conservative (Fig.
1). However, the region
A
sequences from different Pit2 homologs and Pit2(K522E), which
all
support A-MuLV infection in Pit2 backbones, differ only in
positions 1 and 6. Moreover, a comparison of the sequences of
Pit1 region A and
Pit2 region A, which allow similar levels of
infection by A-MuLV in a
human Pit2 context (pOJ80 and Pit2) (
21),
shows two
conserved amino acids (positions 3 and 5) and four conservative
differences (positions 2, 6, 7, and 9). Furthermore, the Pit2/RatPit2
region A and that of pOJ64, which allow A-MuLV infection in Pit1
(pOJ102) and MusPit1 (pOJ64) backbones, respectively, exhibit
amino
acid identity in positions 1 and 9 and show four conservative
differences (positions 2, 5, 6, and 7). Moreover, interestingly,
in
region A of pOJ64, the presence of the threonine residue, resulting
in
A-MuLV receptor function, created a TQEA sequence (region A,
positions
2 through 5). A similar motif is found in the C terminus
of
Pit2/RatPit2 region A (region A, positions 6 through 9) (Fig.
1).
Whether the TQEA motif or the conserved residues actually
play a role
in the A-MuLV receptor function dependent on the receptor
backbone,
however, remains to be investigated.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Region A sequence comparison between receptor constructs
tested for A-MuLV receptor function. Pit2, the human A-MuLV receptor
(26); RatPit2, the rat Pit2 homolog (15); HaPit2,
the hamster Pit2 homolog (29); Pit2(K522E), Pit2 with lysine
at position 522 replaced with glutamic acid (6); pOJ80, Pit2
with region A replaced by the Pit1 region A (21); MusPit1,
the M. musculus musculus Pit1 homolog (9;
also this study); pOJ64, MusPit1 with a threonine inserted between
lysine (position 553) and glutamine (position 554)
(10; also this study); pOJ102, Pit1 with region A
replaced by the Pit2 region A (21); Pit1, the human GALV
receptor (16). Positions 1 to 9 of region A correspond to
positions 522 to 530 in Pit2 homologs, pOJ80, and Pit2(K522E);
positions 550 to 558 in Pit1 and pOJ102; and positions 553 to 561 in
pOJ64. The dash at position 1 indicates a gap, and positions 2 to 9 correspond to positions 553 to 560 in MusPit1.
|
|
Roles of loops 2 and 4 in 10A1 receptor function.
Pit1
(pOJ75), MusPit1 (pOJ19), and Pit2 (pOJ74) were found to support 10A1
infection efficiently (Table 1) in agreement with previous observations
(14). The construct pOJ64 derived from MusPit1 by insertion
of a threonine in region A also supported 10A1 infection. However, the
introduction of MusPit1 region A in Pit1 (pOJ34) reduced 10A1 infection
to a level just above background, indicating that region A also can
influence 10A1 receptor function. In a wild-type MusPit1 backbone,
MusPit1 region A is compatible with 10A1 receptor function. Between
MusPit1 and pOJ34, the only differences in the extracellular loops
besides those in region A are found in loop 2 [MusPit1/pOJ34 positions
149(N)/145(K) and 152(K)/148(E)] (9, 10). These results
indicate that both loops 2 and 4 are involved in 10A1 receptor function
and that whether a certain region A sequence is permissive for 10A1
infection is dependent on the sequence present in loop 2 of the
protein.
The human Pit1-derived constructs pOJ36, harboring a scrambled region A
sequence, and pOJ71, with the aspartic acid in position
550 deleted,
did not promote 10A1 entry. These observations are
in agreement with a
possible role of region A in 10A1 infection;
it is, however, not known
whether the proteins encoded by pOJ36
and pOJ71 are present on the cell
surface, in that they do not
support infection by any of the tested
viruses (Table
1) (
10,
23).
The observation that substitution of Pit1 region A for the
corresponding MusPit1 sequence (pOJ34) reduced 10A1 receptor function
is interesting given the broad receptor usage of 10A1. On the
other
hand, 10A1 and A-MuLV show only six amino acid differences
in the
N-terminal part of the SU protein (
18), three of which
are
found in the variable regions A and B which have been suggested
to be
directly involved in receptor recognition by C-type viruses
(
2,
3,
7). It is therefore not unlikely that A-MuLV and
10A1 depend on
the same receptor domain(s) for infection. In addition
to the
C-terminal region A sequences, our results also indicated
a role of
N-terminal loop 2 sequences in 10A1 entry. Interestingly,
as discussed
above, A-MuLV infection also seems to depend on N-terminal
sequences,
and we are currently undertaking studies to assess
the possible role of
loop 2 in both A-MuLV and 10A1 entry.
Region A sequences are critical for both GALV and FeLV-B infection
(
6,
10,
14,
21-23); e.g., none of the region A mutants
in
Table
1 tested for GALV or FeLV-B receptor function supported
entry by
these viruses (
10,
23). However, results obtained
with
Pit1-Pit2 chimeras revealed that FeLV-B is dependent on other
N- or
C-terminal Pit1 sequences in addition to region A for entry
(
21). The presence of Pit1 region A was sufficient to confer
GALV receptor function on Pit2 (
21). Indeed, a single amino
acid change in Pit2 region A resulted in a functional GALV receptor
(
6,
22). Moreover, the presence of 12 Pit1-specific amino
acids, the C-terminal 9 of which comprise region A, were sufficient
to
confer receptor function for GALV on Pho-4 (
20), a
sodium-dependent
phosphate transporter from
Neurospora
crassa distantly related
to Pit1 and Pit2 (
27).
However, Chaudry and Eiden recently identified
two mutant Pit1 A
regions [positions 550(D) and 553(D) mutated
to 550(G) and 553(G) and
to 550(G) and 553(Q)] which were both
permissive for GALV infection
when present in a Pit1 backbone;
in contrast, when present in a Pit2
backbone, they were not compatible
with efficient GALV infection
(
4). These results indicate that
GALV is also dependent on
sequences in addition to those in region
A for infection. In summary,
the requirements for FeLV-B, GALV,
A-MuLV, and 10A1 receptor function
might be quite similar, all
involving region A in addition to at least
one other receptor
domain. Moreover, we suggest that at least for GALV,
A-MuLV, and
10A1, the sequence requirements for A regions compatible
with
receptor function are dependent on the sequence present in the
other not-yet-identified domain(s) in the receptor.
 |
ACKNOWLEDGMENTS |
We thank Maribeth V. Eiden for the PA317GBN cell line, Alan Rein
for the 10A1 virus clone pRR151, and A. Dusty Miller for the pLNPOZ
plasmid.
This work was supported by the Karen Elise Jensen Foundation and the
Danish Biotechnology Programme.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular and Structural Biology, University of Aarhus, C. F. Møllers Allé, Bldg. 130, DK-8000 Aarhus C, Denmark. Phone: 45 8942 2702. Fax: 45 8619 6500. E-mail: LP{at}mbio.aau.dk.
 |
REFERENCES |
| 1.
|
Adam, M. A.,
N. Ramesh,
A. D. Miller, and W. R. A. Osborne.
1991.
Internal initiation of translation in retroviral vectors carrying picornavirus 5' nontranslated regions.
J. Virol.
65:4985-4990[Abstract/Free Full Text].
|
| 2.
|
Bae, Y.,
S. M. Kingsman, and A. J. Kingsman.
1997.
Functional dissection of the Moloney murine leukemia virus envelope protein gp70.
J. Virol.
71:2092-2099[Abstract].
|
| 3.
|
Battini, J. L.,
J. M. Heard, and O. Danos.
1992.
Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses.
J. Virol.
66:1468-1475[Abstract/Free Full Text].
|
| 4.
|
Chaudry, G. J., and M. V. Eiden.
1997.
Mutational analysis of the proposed gibbon ape leukemia virus binding site in Pit1 suggests that other regions are important for infection.
J. Virol.
71:8078-8081[Abstract].
|
| 5.
|
Chien, M.-L.,
J. L. Foster,
J. L. Douglas, and J. V. Garcia.
1997.
The amphotropic murine leukemia virus receptor gene encodes a 71-kilodalton protein that is induced by phosphate depletion.
J. Virol.
71:4564-4570[Abstract].
|
| 6.
|
Eiden, M. V.,
K. B. Farrell, and C. A. Wilson.
1996.
Substitution of a single amino acid residue is sufficient to allow the human amphotropic murine leukemia virus receptor to also function as a gibbon ape leukemia virus receptor.
J. Virol.
70:1080-1085[Abstract].
|
| 7.
|
Fass, D.,
R. A. Davey,
C. A. Hamson,
P. S. Kim,
J. M. Cunningham, and J. M. Berger.
1997.
Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution.
Science
277:1662-1666[Abstract/Free Full Text].
|
| 8.
|
Gorman, C.
1985.
High efficiency gene transfer into mammalian cells, p. 143-190.
In
D. M. Glover (ed.), DNA cloning, vol. II. A practical approach. IRL Press, Oxford, United Kingdom.
|
| 9.
|
Johann, S. V.,
J. J. Gibbons, and B. O'Hara.
1992.
GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus.
J. Virol.
66:1635-1640[Abstract/Free Full Text].
|
| 10.
|
Johann, S. V.,
M. van Zeijl,
J. Cekleniak, and B. O'Hara.
1993.
Definition of a domain of GLVR1 which is necessary for infection by gibbon ape leukemia virus and which is highly polymorphic between species.
J. Virol.
67:6733-6736[Abstract/Free Full Text].
|
| 11.
|
Kavanaugh, M. P.,
D. G. Miller,
W. Zhang,
W. Law,
S. L. Kozak,
D. Kabat, and A. D. Miller.
1994.
Cell surface receptors for gibbon ape leukemia virus and amphotropic murine leukemia virus are inducible sodium-dependent phosphate transporters.
Proc. Natl. Acad. Sci. USA
91:7071-7075[Abstract/Free Full Text].
|
| 12.
|
McLachlin, J. R.,
N. Mittereder,
M. B. Daucher,
M. Kadan, and M. A. Eglitis.
1993.
Factors affecting retroviral vector function and structural integrity.
Virology
195:1-5[Medline].
|
| 13.
|
Miller, A. D., and G. J. Rosman.
1989.
Improved retroviral vectors for gene transfer and expression.
BioTechniques
7:980-990.
[Medline] |
| 14.
|
Miller, D. G., and A. D. Miller.
1994.
A family of retroviruses that utilize related phosphate transporters for cell entry.
J. Virol.
68:8270-8276[Abstract/Free Full Text].
|
| 15.
|
Miller, D. G.,
R. H. Edwards, and A. D. Miller.
1994.
Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus.
Proc. Natl. Acad. Sci. USA
91:78-82[Abstract/Free Full Text].
|
| 16.
|
O'Hara, B.,
S. V. Johann,
H. P. Klinger,
D. G. Blair,
H. Rubinson,
K. J. Dunn,
P. Sass,
S. M. Vitek, and T. Robins.
1990.
Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus.
Cell Growth Differ.
1:119-127[Abstract].
|
| 17.
|
Olah, Z.,
C. Lehel,
W. B. Anderson,
M. V. Eiden, and C. A. Wilson.
1994.
The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter.
J. Biol. Chem.
269:25426-25431[Abstract/Free Full Text].
|
| 18.
|
Ott, D., and A. Rein.
1992.
Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU.
J. Virol.
66:4632-4638[Abstract/Free Full Text].
|
| 19.
|
Ott, D.,
J. Keller,
K. Sill, and A. Rein.
1992.
Phenotypes of murine leukemia virus-induced tumors: influence of 3' viral coding sequences.
J. Virol.
66:6107-6116[Abstract/Free Full Text].
|
| 20.
|
Pedersen, L.,
M. van Zeijl,
S. V. Johann, and B. O'Hara.
1997.
Fungal phosphate transporter serves as a receptor backbone for gibbon ape leukemia virus.
J. Virol.
71:7619-7622[Abstract].
|
| 21.
|
Pedersen, L.,
S. V. Johann,
M. van Zeijl,
F. S. Pedersen, and B. O'Hara.
1995.
Chimeras of receptors for gibbon ape leukemia virus/feline leukemia virus B and amphotropic murine leukemia virus reveal different modes of receptor recognition by retrovirus.
J. Virol.
69:2401-2405[Abstract].
|
| 22.
|
Schneiderman, R. D.,
K. B. Farrell,
C. A. Wilson, and M. V. Eiden.
1996.
The Japanese feral mouse Pit1 and Pit2 homologs lack an acidic residue at position 550 but still function as gibbon ape leukemia virus receptors: implications for virus binding motif.
J. Virol.
70:6982-6986[Abstract/Free Full Text].
|
| 23.
|
Tailor, C. S.,
Y. Takeuchi,
B. O'Hara,
S. V. Johann,
R. A. Weiss, and M. K. Collins.
1993.
Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections.
J. Virol.
67:6737-6741[Abstract/Free Full Text].
|
| 24.
|
Takeuchi, Y.,
R. G. Vile,
G. Simpson,
B. O'Hara,
M. K. Collins, and R. A. Weiss.
1992.
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus.
J. Virol.
66:1219-1222[Abstract/Free Full Text].
|
| 25.
|
Turner, D. L., and C. L. Cepko.
1987.
A common progenitor for neurons and glia cells persists in rat retina late in development.
Nature
328:131-136[Medline].
|
| 26.
|
van Zeijl, M.,
S. V. Johann,
E. Closs,
J. Cunningham,
R. Eddy,
T. B. Shows, and B. O'Hara.
1994.
A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family.
Proc. Natl. Acad. Sci. USA
91:1168-1172[Abstract/Free Full Text].
|
| 27.
|
Versaw, W. K., and R. L. Metzenberg.
1995.
Repressible cation-phosphate symporters in Neurospora crassa.
Proc. Natl. Acad. Sci. USA
92:3883-3887.
|
| 28.
|
Wilson, C. A.,
K. B. Farrell, and M. V. Eiden.
1994.
Comparison of cDNAs encoding the gibbon ape leukaemia virus receptor from susceptible and non-susceptible murine cells.
J. Gen. Virol.
75:1901-1908[Abstract/Free Full Text].
|
| 29.
|
Wilson, C. A.,
K. B. Farrell, and M. V. Eiden.
1994.
Properties of a unique form of the murine amphotropic leukemia virus receptor expressed on hamster cells.
J. Virol.
68:7697-7703[Abstract/Free Full Text].
|
| 30.
|
Wilson, C. A.,
M. V. Eiden,
W. B. Anderson,
C. Lehel, and Z. Olah.
1995.
The dual-function hamster receptor for amphotropic murine leukemia virus (MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate symporter.
J. Virol.
69:534-537[Abstract].
|
J Virol, May 1998, p. 4524-4527, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bottger, P., Pedersen, L.
(2004). The Central Half of Pit2 Is Not Required for Its Function as a Retroviral Receptor. J. Virol.
78: 9564-9567
[Abstract]
[Full Text]
-
Feldman, S. A, Farrell, K. B., Murthy, R. K., Russ, J. L., Eiden, M. V.
(2004). Identification of an Extracellular Domain within the Human PiT2 Receptor That Is Required for Amphotropic Murine Leukemia Virus Binding. J. Virol.
78: 595-602
[Abstract]
[Full Text]
-
Hein, S., Prassolov, V., Zhang, Y., Ivanov, D., Lohler, J., Ross, S. R., Stocking, C.
(2003). Sodium-Dependent myo-Inositol Transporter 1 Is a Cellular Receptor for Mus cervicolor M813 Murine Leukemia Virus. J. Virol.
77: 5926-5932
[Abstract]
[Full Text]
-
Barnett, A. L., Wensel, D. L., Li, W., Fass, D., Cunningham, J. M.
(2003). Structure and Mechanism of a Coreceptor for Infection by a Pathogenic Feline Retrovirus. J. Virol.
77: 2717-2729
[Abstract]
[Full Text]
-
Bottger, P., Pedersen, L.
(2002). Two Highly Conserved Glutamate Residues Critical for Type III Sodium-dependent Phosphate Transport Revealed by Uncoupling Transport Function from Retroviral Receptor Function. J. Biol. Chem.
277: 42741-42747
[Abstract]
[Full Text]
-
Lauring, A. S., Cheng, H. H., Eiden, M. V., Overbaugh, J.
(2002). Genetic and Biochemical Analyses of Receptor and Cofactor Determinants for T-Cell-Tropic Feline Leukemia Virus Infection. J. Virol.
76: 8069-8078
[Abstract]
[Full Text]
-
Overbaugh, J., Miller, A. D., Eiden, M. V.
(2001). Receptors and Entry Cofactors for Retroviruses Include Single and Multiple Transmembrane-Spanning Proteins as well as Newly Described Glycophosphatidylinositol-Anchored and Secreted Proteins. Microbiol. Mol. Biol. Rev.
65: 371-389
[Abstract]
[Full Text]
-
Dreyer, K., Pedersen, F. S., Pedersen, L.
(2000). A 13-Amino-Acid Pit1-Specific Loop 4 Sequence Confers Feline Leukemia Virus Subgroup B Receptor Function upon Pit2. J. Virol.
74: 2926-2929
[Abstract]
[Full Text]
-
Tailor, C. S., Nouri, A., Kabat, D.
(2000). A Comprehensive Approach to Mapping the Interacting Surfaces of Murine Amphotropic and Feline Subgroup B Leukemia Viruses with Their Cell Surface Receptors. J. Virol.
74: 237-244
[Abstract]
[Full Text]
-
Lundorf, M. D., Pedersen, F. S., O'Hara, B., Pedersen, L.
(1999). Amphotropic Murine Leukemia Virus Entry Is Determined by Specific Combinations of Residues from Receptor Loops 2 and 4. J. Virol.
73: 3169-3175
[Abstract]
[Full Text]